Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?

Millennium Management more than doubled its AbbVie position by adding 840,718 shares, bringing its stake to roughly 1.5 million shares valued at about $380 million. AbbVie's Skyrizi and Rinvoq generated first-half 2026 net sales of $9.99 billion and $4.64 billion, respectively, while its 2.7% dividend yield is supported by a $6.83 annual payout that has grown at a 5.9% five-year CAGR. The article flags valuation risk, with AbbVie's 7.2x price-to-sales ratio above 6.3x at March-end and 5.7x a year earlier, alongside acquisition-related debt concerns including its $11 billion Apogee Therapeutics purchase.

Analysis

The investable issue is whether AbbVie can sustain a premium multiple while its growth mix shifts from mature cash generators toward immunology and aesthetics. Skyrizi/Rinvoq operating leverage should support earnings through the next 12-24 months, but the market is already capitalizing much of that durability; incremental upside requires continued share gains and limited payer pressure rather than merely in-line growth. The dividend constrains downside for income-oriented holders, but it does not offset a de-rating risk if net leverage rises faster than acquired revenue and synergies.

Millennium's disclosed ownership change is a weak standalone signal: multi-manager filings are delayed, can reflect factor-book construction or hedged exposures, and do not establish conviction in the underlying. The more consequential second-order read is that AbbVie's acquisition appetite could tighten the valuation of differentiated late-stage immunology assets, benefiting APGE and similar specialty-biopharma targets, while raising the risk that ABBV pays peak-cycle prices to extend its pipeline. Watch for whether any deal is financed with incremental debt versus divestitures and operating cash flow; the former would make the equity increasingly rate-sensitive.

Near term, ABBV is likely range-bound absent an earnings revision, clinical readout, or new business-development announcement. Over 1-3 months, consensus upgrades are plausible if immunology growth offsets erosion elsewhere, but a miss on volume, gross-to-net pricing, or aesthetics demand would expose the stock's premium revenue multiple. Over 6-18 months, the key falsifier is a material slowdown in Skyrizi/Rinvoq growth before pipeline launches can replace it; that would turn the dividend from a valuation support into a capital-allocation constraint.

Key Decisions for Investors

• Maintain a neutral-to-modest long ABBV only on 5-8% pullbacks or after confirmation of upward 2027 EPS revisions; target mid-single-digit earnings growth plus dividend carry, with upside dependent on multiple stability. Exit or hedge if quarterly immunology growth decelerates materially versus consensus or net-debt-to-EBITDA trends upward after M&A.
• Use a 3-6 month pair trade: long ABBV / short a broad large-cap pharma proxy such as PPH if AbbVie demonstrates continued immunology share gains. This isolates execution relative to the group; stop out if ABBV underperforms PPH by 8-10% following earnings, which would signal a company-specific multiple reset.
• Treat APGE as an M&A optionality watchlist rather than a recommended acquisition-arbitrage long. Initiate only after reviewing its clinical differentiation, cash runway, and implied takeover premium; ABBV's strategic need can support target valuations, but a failed trial or a buyer choosing internal pipeline investment would sharply impair the thesis.
• Do not infer a trade from SPCX or NVDA based on the reported portfolio activity. Neither has a demonstrated earnings linkage to ABBV's core cash-flow trajectory, and the disclosed manager positioning may be hedged or stale.